Shenzhen JXBio Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Shenzhen JYMed Technology Co., Ltd., specializing in the research, development, production, and sales of peptide-based pharmaceuticals. As an innovative pharmaceutical enterprise with independent intellectual property rights, company was established in 2013 with a registered capital of 30 million RMB. The company has built four GMP-compliant formulation production lines.

Company primarily focuses on the production of peptide formulations and the preparation of formulation samples for certain projects within its CDMO services. Its key production capabilities include cartridge-based injections, small-volume injections, and lyophilized powder injections. The company has developed an integrated service platform that covers the entire process from peptide API production to final formulation manufacturing. Currently, company has obtained the National Medical Products Administration (NMPA) approval for Terlipressin Injection.

With a strong technological foundation spanning from peptide research to industrial-scale manufacturing, company adheres to strict GMP production management practices. The company ensures rigorous compliance with GMP standards, implementing precise quality control measures throughout the entire production process. This includes adherence to detailed process specifications, standard operating procedures (SOPs) for positions and equipment, as well as strict hygiene and cleanliness protocols, guaranteeing the safety, efficacy, and consistent quality of its products.